scholarly journals Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients

2016 ◽  
Vol 68 (11) ◽  
pp. 1223-1232 ◽  
Author(s):  
Dimitrios Alexopoulos ◽  
Ioanna Xanthopoulou ◽  
Athanasios Moulias ◽  
John Lekakis
Keyword(s):  
Myocardial Infarction ◽  
Post Myocardial Infarction ◽  
P2y12 Receptor ◽  
Receptor Antagonists

Cumulative exposure to particulate matter air pollution and long-term post-myocardial infarction outcomes

2013 ◽  
Vol 57 (4) ◽  
pp. 339-344 ◽  
Author(s):  
Silvia Koton ◽  
Noa Molshatzki ◽  
Yuval ◽  
Vicki Myers ◽  
David M. Broday ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Air Pollution ◽  
Particulate Matter ◽  
Post Myocardial Infarction ◽  
Cumulative Exposure

Long-Term Use of Minidose Heparin in Post-Myocardial Infarction

1975 ◽  
pp. 341-350 ◽  
Author(s):  
Menard M. Gertler ◽  
Hillar E. Leetma ◽  
Russell J. Koutrouby ◽  
Elyse D. Johnson
Keyword(s):  
Myocardial Infarction ◽  
Post Myocardial Infarction

Mineralocorticoid receptor antagonists

ESC CardioMed ◽  
2018 ◽  
pp. 167-173
Author(s):  
Faiez Zannad ◽  
João Pedro Ferreira
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Adverse Effects ◽  
Beneficial Effect ◽  
Mechanism Of Action ◽  
Mineralocorticoid Receptor ◽  
Post Myocardial Infarction ◽  
Mineralocorticoid Receptor Antagonists ◽  
Receptor Antagonists ◽  
Clinical Syndromes

Hypertension, post-myocardial infarction, and heart failure are the cardiovascular clinical syndromes where mineralocorticoid receptor antagonists (MRAs) have shown a beneficial effect. Most guidelines while recommending a MRA do not make a clear recommendation as to which MRA should be used, how doses should be titrated, or which monitorization is indicated. This chapter provides an appraisal of the different types of MRA drugs and their pharmacological differences with respect to mechanism of action, pharmacokinetics, monitoring, adverse effects, and drug interactions.

scholarly journals Effects of antidepressant treatment following myocardial infarction

2007 ◽  
Vol 190 (6) ◽  
pp. 460-466 ◽  
Author(s):  
Joost P. van Melle ◽  
Peter de Jonge ◽  
Adriaan Honig ◽  
Aart H. Schene ◽  
Astrid M. G. Kuyper ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Antidepressant Treatment ◽  
Controlled Trial ◽  
Intervention Group ◽  
Post Myocardial Infarction ◽  
Cardiac Events ◽  
Long Term Depression ◽  
Depression Status ◽  
Icd 10

BackgroundDepression following myocardial infarction is associated with poor cardiac prognosis. It is unclear whether antidepressant treatment improves long-term depression status and cardiac prognosis.AimsTo evaluate the effects of antidepressant treatment compared with usual care in an effectiveness study.MethodIn a multicentre randomised controlled trial, 2177 myocardial infarction patients were evaluated for ICD–10 depression and randomised to intervention (n=209) or care as usual (n=122). Both arms were evaluated at 18 months post-myocardial infarction for long-term depression status and new cardiac events.ResultsNo differences were observed between intervention and control groups in mean scores on the Beck Depression Inventory (11.0, s.d.=7.5 v. 10.2, s.d.=5.l, P=0.45) or presence of ICD-10 depression (30.5 v. 32.1%, P=0.68). The cardiac event rate was 14% among the intervention group and 13% among controls (OR=1.07, 95% CI 0.57-2.00).ConclusionsAntidepressant treatment did not alter long-term depression post-myocardial infarction status or improve cardiac prognosis.

Sign in / Sign up

Export Citation Format

Share Document